Laura V. Doyle

1.8k total citations
27 papers, 1.5k citations indexed

About

Laura V. Doyle is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Laura V. Doyle has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Laura V. Doyle's work include Immunotherapy and Immune Responses (7 papers), Immune Cell Function and Interaction (6 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Laura V. Doyle is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Immune Cell Function and Interaction (6 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Laura V. Doyle collaborates with scholars based in United States, Switzerland and Germany. Laura V. Doyle's co-authors include Nitin K. Damle, E C Bradley, C R Vitt, J R Bender, H Y Min, Marc A. Shuman, Jennifer R. Stratton-Thomas, Susan M. Rosenberg, Catherine Zandonella and Leo S. Lin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Biotechnology.

In The Last Decade

Laura V. Doyle

25 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura V. Doyle United States 17 748 500 393 272 190 27 1.5k
Dian L. Olson United States 15 890 1.2× 764 1.5× 383 1.0× 328 1.2× 188 1.0× 18 1.8k
Monika Raab Germany 23 786 1.1× 723 1.4× 440 1.1× 169 0.6× 276 1.5× 38 1.7k
Cinda M. Boyer United States 18 656 0.9× 620 1.2× 537 1.4× 260 1.0× 127 0.7× 31 1.5k
S A Cannistra United States 11 502 0.7× 816 1.6× 644 1.6× 402 1.5× 113 0.6× 11 2.4k
Juan J. Roman United States 23 599 0.8× 568 1.1× 728 1.9× 191 0.7× 145 0.8× 27 1.8k
E B Bröcker Germany 19 614 0.8× 653 1.3× 442 1.1× 197 0.7× 116 0.6× 27 1.5k
Kazushi Shigemasa Japan 27 271 0.4× 840 1.7× 636 1.6× 441 1.6× 209 1.1× 50 1.8k
Naoki Watanabe Japan 21 380 0.5× 527 1.1× 220 0.6× 124 0.5× 72 0.4× 72 1.2k
Sandra Coral Italy 25 1.1k 1.4× 1.6k 3.1× 691 1.8× 270 1.0× 85 0.4× 53 2.3k
Robert L. Cohen United States 14 449 0.6× 1.2k 2.4× 528 1.3× 840 3.1× 264 1.4× 23 2.2k

Countries citing papers authored by Laura V. Doyle

Since Specialization
Citations

This map shows the geographic impact of Laura V. Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura V. Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura V. Doyle more than expected).

Fields of papers citing papers by Laura V. Doyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura V. Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura V. Doyle. The network helps show where Laura V. Doyle may publish in the future.

Co-authorship network of co-authors of Laura V. Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of Laura V. Doyle. A scholar is included among the top collaborators of Laura V. Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura V. Doyle. Laura V. Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Doyle, Laura V., Kieran Wynne, Alfonso Blanco, et al.. (2025). The fibrin-derived peptide FX06 protects human pulmonary endothelial cells against the COVID-19-triggered cytokine storm. Frontiers in Immunology. 16. 1591860–1591860.
2.
Kuo, Tracy C., Amy Chen, Ons Harrabi, et al.. (2020). Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology. 13(1). 160–160. 58 indexed citations
3.
Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2020). 615 Targeted immune cell activation by systemic delivery of toll-like receptor 9 agonist antibody conjugates induce potent anti-tumor immunity. SHILAP Revista de lepidopterología. A369.2–A370.
4.
Sockolosky, Jonathan T., Emma Sangalang, Shelley Izquierdo, et al.. (2019). Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα. mAbs. 11(6). 1036–1052. 39 indexed citations
5.
Lan, Jiong, Abran Costales, Gordana Atallah, et al.. (2018). Design and synthesis of potent RSK inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(19). 3197–3201. 10 indexed citations
6.
Kauder, Steven E., Tracy C. Kuo, Ons Harrabi, et al.. (2018). ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE. 13(8). e0201832–e0201832. 121 indexed citations
7.
8.
Lan, Jiong, Abran Costales, Gordana Atallah, et al.. (2015). Discovery of Potent and Selective RSK Inhibitors as Biological Probes. Journal of Medicinal Chemistry. 58(17). 6766–6783. 50 indexed citations
9.
Aronchik, Ida, B.A. Appleton, Stephen E. Basham, et al.. (2014). Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. Molecular Cancer Research. 12(5). 803–812. 61 indexed citations
10.
Costales, Abran, Savithri Ramurthy, Jiong Lan, et al.. (2014). 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(6). 1592–1596. 24 indexed citations
11.
Taverna, Pietro, Katherine G. Rendahl, Dragana Jekic-McMullen, et al.. (2006). Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts. Biochemical Pharmacology. 73(1). 44–55. 5 indexed citations
12.
Fong, Susan, Michael Doyle, Robert J. Goodson, et al.. (2002). Random Peptide Bacteriophage Display as a Probe for Urokinase Receptor Ligands. Biological Chemistry. 383(1). 149–58. 6 indexed citations
13.
Ballinger, Marcus, Venkatakrishna Shyamala, Laura V. Doyle, et al.. (1999). Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nature Biotechnology. 17(12). 1199–1204. 56 indexed citations
14.
Tressler, Robert, Jennifer Stratton, Shaoqiu Zhuo, et al.. (1999). Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. Apmis. 107(1-6). 168–173. 42 indexed citations
15.
Min, H Y, Laura V. Doyle, C R Vitt, et al.. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.. PubMed. 56(10). 2428–33. 218 indexed citations
16.
Fong, Susan, Laura V. Doyle, James J. Devlin, & Michael Doyle. (1994). Scanning whole cells with phage‐display libraries: Identification of peptide ligands that modulate cell function. Drug Development Research. 33(2). 64–70. 23 indexed citations
17.
18.
19.
Damle, Nitin K. & Laura V. Doyle. (1987). Interleukin‐2 activated human killer lymphocytes: Lack of involvement of interferon in the development of IL‐2‐activated killer lymphocytes. International Journal of Cancer. 40(4). 519–524. 10 indexed citations
20.
Damle, Nitin K., Laura V. Doyle, J R Bender, & E C Bradley. (1987). Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.. The Journal of Immunology. 138(6). 1779–1785. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dian L. Olson Breakdown of academic impact, for papers by Monika Raab Breakdown of academic impact, for papers by Cinda M. Boyer Breakdown of academic impact, for papers by S A Cannistra Breakdown of academic impact, for papers by Juan J. Roman Breakdown of academic impact, for papers by E B Bröcker Breakdown of academic impact, for papers by Kazushi Shigemasa Breakdown of academic impact, for papers by Naoki Watanabe Breakdown of academic impact, for papers by Sandra Coral Breakdown of academic impact, for papers by Robert L. Cohen
Rankless by CCL
2026